Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Launched by NATIONAL CANCER CENTRE, SINGAPORE · Apr 6, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to find specific markers in blood and tissue samples that can help predict how sensitive different cancers are to radiation treatment. It focuses on patients with cancers like nasopharyngeal cancer and prostate cancer, particularly those who have either experienced significant side effects from radiation or have tumors that are known to respond well to this type of therapy. By understanding these biomarkers, doctors hope to improve treatment plans and minimize side effects for future patients.
To participate in this study, patients need to be between 21 and 98 years old and must have had severe side effects from radiation therapy or have a cancer that is sensitive to radiation. Participants will provide blood and tissue samples, which will be analyzed for genetic and biochemical information. This research is important because it may help tailor cancer treatments more effectively and safely for individuals based on their unique responses to radiation. The study is currently recruiting participants of all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with severe side effects from radiotherapy
- • Patients with a type of cancer that is associated with sensitivity to radiotherapy
- Exclusion Criteria:
- • Age of patient must be between 21 (inclusive) and 99 (exclusive)
About National Cancer Centre, Singapore
The National Cancer Centre Singapore (NCCS) is a leading institution dedicated to cancer treatment, research, and education in Asia. As a premier clinical trial sponsor, NCCS focuses on advancing oncology through innovative therapies and comprehensive clinical studies. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to improving patient outcomes and contributing to global cancer research initiatives. NCCS actively collaborates with various stakeholders, including academic institutions and pharmaceutical companies, to foster groundbreaking discoveries and enhance the understanding of cancer management and treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Melvin Chua, MD
Principal Investigator
National Cancer Centre, Singapore
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials